Described herein is a synergistic combination comprising a quorum-sensing inhibitor and/or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and/or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The present disclosure discloses application of a microbiota-derived plasmalogens to treatment of colon cancer, and belongs to the technical field of biomedicine and microorganisms. The microbiota-derived plasmalogens provided in the present disclosure is extracted from an anaerobic microorganism including any one or more of Lactobacillaceae, Bifidobacterium, Clostridium butyricum, and Peptostreptococcus Kluyver and van Niel after fermentation. The microbiota-derived plasmalogens can reduce expressions of colon cancer-associated cytokines at the molecular level, inhibit the proliferation of colon cancer cells, and reduce the number and size of colon adenomas in patients with colon cancer. The microbiota-derived plasmalogens can be used as an effective nutrition strategy for preventing and treating the colon cancer, and a theoretical support is provided for efficient utilization of the enteric microbiota-derived plasmalogens.

The present disclosure discloses application of a microbiota-derived plasmalogens to treatment of colon cancer, and belongs to the technical field of biomedicine and microorganisms. The microbiota-derived plasmalogens provided in the present disclosure is extracted from an anaerobic microorganism including any one or more of Lactobacillaceae, Bifidobacterium, Clostridium butyricum, and Peptostreptococcus Kluyver and van Niel after fermentation. The microbiota-derived plasmalogens can reduce expressions of colon cancer-associated cytokines at the molecular level, inhibit the proliferation of colon cancer cells, and reduce the number and size of colon adenomas in patients with colon cancer. The microbiota-derived plasmalogens can be used as an effective nutrition strategy for preventing and treating the colon cancer, and a theoretical support is provided for efficient utilization of the enteric microbiota-derived plasmalogens.

Provided are compositions and methods for treatment of inflammatory bowel disease. The compositions comprise Odoribacter and/or Alistipes bacteria, identified herein as being core transferable bacteria in fecal matter transfer therapies. Methods are also provided comprising administering to an individual suffering from IBD a composition comprising Odoribacter and/or Alistipes bacteria.

Provided are compositions and methods for treatment of inflammatory bowel disease. The compositions comprise Odoribacter and/or Alistipes bacteria, identified herein as being core transferable bacteria in fecal matter transfer therapies. Methods are also provided comprising administering to an individual suffering from IBD a composition comprising Odoribacter and/or Alistipes bacteria.

Provided are compositions and methods for treatment of inflammatory bowel disease. The compositions comprise Odoribacter and/or Alistipes bacteria, identified herein as being core transferable bacteria in fecal matter transfer therapies. Methods are also provided comprising administering to an individual suffering from IBD a composition comprising Odoribacter and/or Alistipes bacteria.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

Microorganisms are provided, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a CeD-specific antigen (e.g., a gliadin polypeptide comprising at least one HLA-DQ2 specific epitope, at least one deamidated HLA-DQ2 specific epitope, at least one HLA-DQ8 specific epitope, at least one deamidated HLA-DQ8 specific epitope, or a combination of (a) at least one HLA-DQ2-specific epitope and/or at least one deamidated HLA-DQ2 specific epitope, and (b) at least one HLA-DQ8 specific epitope and/or at least one deamidated HLA-DQ8 specific epitope) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. Compositions (e.g., pharmaceutical compositions), methods of using the microorganisms and compositions are provided, e.g., for the treatment of celiac disease (CeD). The microorganism may be administered orally, delivering the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides.